Tagged with Bayer

Singapore Bayer’s Dr Vincent Ruland highlights his career trajectory from medical doctor to pharma country manager; the company’s priorities in Malaysia, Singapore, and Brunei; and leveraging the Asian innovation ecosystem.   The industry tends to foster experts and specialists, but the world is changing so rapidly that we need to be…

Europe With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head of Digital Transformation Saskia Steinacker argues that the time is now for pharma executives to start preparing themselves and their teams for the future.   “We are in Healthcare. We are…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving the evolution of the pharma innovation model. The session was moderated by Deloitte global life sciences and health care leader…

Opinion Michael Levy, head of pharmacovigilance at Bayer Pharma and Bayer Consumer Health, makes a compelling case for the critical role of pharmacovigilance in ensuring ensuring patient safety and future-proofing the global pharma industry amidst the rush to develop and repurpose treatments and vaccines for COVID-19.     The COVID-19 virus…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

Norway Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian pharma industry; Norway’s innovation capabilities in radiopharmaceuticals; and his excitement surrounding Bayer’s portfolio and upcoming product launches in Norway.   Through the acquisition and integration of Algeta,…

Switzerland Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his leadership and talent management philosophy, the investment and commitment Bayer is making towards becoming a global oncology player, as well as his perspectives on digital…

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…

Mexico A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA, Sanfer, Senosiain and Siegfried Rhein.   1. Sanofi Global CEO: Paul Hudson Country Chair: Fernando Sampaio Sanofi has had a…

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

Long Read Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on chasing demand in the decidedly more populous Asian market space. But, with an estimated annual growth rate of 10 percent,…